Development of a novel anti‐amyloid therapeutic: an orally administrable anti‐abeta‐oligomer compound in early preventative intervention

Abstract

Background: Over the past decade, the Multhaup lab have evaluated the safety and efficacy of a protease resistant D‐amino acid A β‐ I nteracting P eptide (D‐AIP) as a novel anti‐amyloid preventive strategy, which targets Aβ accumulation as the primary event in Alzheimer disease (AD) pathogenesis.

The paper